If in-depth in vivo/vitro studies can be conducted on this basis to clarify the mechanism of these regulators (TRMT6, TRMT61A, TRMT10C, and YTHDF1), they will provide promising targeted intervention strategies for HCC therapy. The gene discussed is TRMT6; the disease is hepatocellular carcinoma.